| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
423 Stock Overview
Dong-E-E-Jiao Co.,Ltd. produces and sells traditional Chinese medicines, biological drugs, and health food products in China.
Dong-E-E-Jiao Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥36.88 |
| 52 Week High | CN¥50.12 |
| 52 Week Low | CN¥27.60 |
| Beta | 1.05 |
| 1 Month Change | -3.25% |
| 3 Month Change | 14.89% |
| 1 Year Change | 17.04% |
| 3 Year Change | 19.55% |
| 5 Year Change | -41.81% |
| Change since IPO | 2,204.70% |
Recent News & Updates
Shareholder Returns
| 423 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0.2% | 1.6% | 2.3% |
| 1Y | 17.0% | -17.5% | -11.7% |
Return vs Industry: 000423 exceeded the CN Pharmaceuticals industry which returned -17.5% over the past year.
Return vs Market: 000423 exceeded the CN Market which returned -11.7% over the past year.
Price Volatility
| 423 volatility | |
|---|---|
| 423 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in CN Market | 9.2% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 000423 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 000423's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 4,180 | Dengfeng Gao | https://www.dongeejiao.com |
Dong-E-E-Jiao Co.,Ltd. produces and sells traditional Chinese medicines, biological drugs, and health food products in China. Dong-E-E-Jiao Co.,Ltd.
Dong-E-E-Jiao Co.,Ltd. Fundamentals Summary
| 423 fundamental statistics | |
|---|---|
| Market Cap | CN¥23.07b |
| Earnings (TTM) | CN¥493.47m |
| Revenue (TTM) | CN¥4.01b |
48.1x
P/E Ratio5.9x
P/S RatioIs 423 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 423 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.01b |
| Cost of Revenue | CN¥1.64b |
| Gross Profit | CN¥2.37b |
| Other Expenses | CN¥1.87b |
| Earnings | CN¥493.47m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.77 |
| Gross Margin | 59.12% |
| Net Profit Margin | 12.32% |
| Debt/Equity Ratio | 0% |
How did 423 perform over the long term?
See historical performance and comparison